INCAGN02385

Phase 2Biologic

Incyte

INCAGN02385 is one of 117 biologic programs targeting Endometrial Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

116

Competitors

Pipeline

Status by Indication[3][1]

Indication

Endometrial CancerActive, not recruiting

Urothelial CarcinomaActive, not recruiting

Squamous Cell CarcinomaActive, not recruiting

Endometrial CancerPhase 2

Active, not recruiting

Urothelial CarcinomaPhase 2

Active, not recruiting

Squamous Cell CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

279 competitors in Squamous Cell Carcinoma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

20 2

Taxol

Teva

Phase 3

11 3

Tecentriq

Roche

Phase 3

6 4

Paraplatin

AAvyxa

Phase 3

19 5

Libtayo

Regeneron

Phase 3

5 6

Yervoy

Bristol-Myers Squibb

Phase 3

4 7

Vectibix

Amgen

Phase 3

3 8

Beyfortus

BeiGene

Phase 3

2 9

Gilotrif

Boehringer Ingelheim

Phase 3

10 10

Tarceva

DDutch Society of Physicians for Pulmonology and Tuberculosis

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Advanced Malignancies2 trials

Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

Completed· Incyte logo

Incyte·Phase 1/2·NCT04370704·61 enrolled

A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

Completed·IIncyte Biosciences International Sàrl·Phase 1·NCT03538028·22 enrolled

Urothelial Carcinoma1 trial

An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma

Terminated· Incyte logo

Incyte·Phase 2·NCT04586244·30 enrolled

Squamous Cell Carcinoma1 trial

Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Active, not recruiting·IIncyte Biosciences International Sàrl·Phase 2·NCT05287113·176 enrolled

Endometrial Cancer1 trial

Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.

Active, not recruiting· Incyte logo

Incyte·Phase 2·NCT04463771·206 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for INCAGN02385. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — INCAGN02385 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for INCAGN02385. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Incyte company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: Incyte

INCAGN02385

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Advanced Malignancies2 trials

Urothelial Carcinoma1 trial

Squamous Cell Carcinoma1 trial

Endometrial Cancer1 trial

References

Drug Info

Quick Facts

Related News